糖尿病'},

Photorealistic lab illustration depicting diverse drug-resistant E. coli strains from global diabetic foot infection study, with petri dishes, world map genomics, and scientists analyzing data.

Global genomic study finds highly diverse E. coli strains in diabetic foot infections, including drug-resistant lineages

January 20, 2026 由 AI 报道 AI 生成的图像事实核查

A genomic analysis of Escherichia coli isolated from infected diabetic foot ulcers across 10 countries found no single dominant strain, instead revealing wide genetic diversity and a subset of isolates with markers of multidrug or extensive drug resistance, researchers from King’s College London and the University of Westminster report.

Anvisa expands indications for Wegovy and Ozempic to cardiovascular risks

Brazil's Anvisa approved on Monday, February 2, 2026, the expansion of therapeutic indications for semaglutide, the active ingredient in Wegovy and Ozempic. Wegovy can now be used to reduce the risk of heart attacks and strokes in adults with cardiovascular disease and overweight, while Ozempic is indicated for type 2 diabetes associated with chronic kidney disease. The agency is also reviewing a request for an oral version of Wegovy.

高血糖增加龋齿风险，大阪研究发现

February 02, 2026 由 AI 报道

大阪大学研究人员发现，持续高血糖水平会提高龋齿风险，因为糖分从血液转移到唾液。在对约60名糖尿病和非糖尿病个体的调查中，较高的血糖与唾液中葡萄糖和果糖增加，以及龋齿和牙菌斑增加相关。

健康

Tufts engineers bacteria to produce rare healthy sugar

健康

Survey finds limited public awareness of CKM syndrome, which is tied to risk factors common in U.S. adults

健康

Study links common food preservatives to type 2 diabetes risk

Abbott launches AI feature to aid diabetes meal choices

Health care company Abbott has introduced Libre Assist, a new AI-powered tool within its Libre app, designed to help people with diabetes assess the potential impact of their meals on glucose levels before eating. Users can simply photograph or describe their food to receive predictions and tips. The feature, unveiled at CES 2026, integrates with Abbott's FreeStyle Libre continuous glucose monitors for post-meal insights.

Study finds type 2 diabetes reshapes human heart structure

January 04, 2026 由 AI 报道

Researchers at the University of Sydney have discovered that type 2 diabetes directly alters the heart's structure and energy production, increasing the risk of heart failure. By examining donated human heart tissue, the team identified molecular changes that stiffen the muscle and disrupt cellular function. These findings, published in EMBO Molecular Medicine, highlight a unique profile in patients with both diabetes and ischemic heart disease.

Oral β2-agonist targeting muscle metabolism shows promise for type 2 diabetes and obesity

Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.

FGF19 hormone activates brain pathway to boost fat burning in obese mice

December 06, 2025 由 AI 报道事实核查

A study in obese mice has found that the gut-derived hormone FGF19 can signal the brain to increase energy expenditure and activate fat-burning cells. Acting through the hypothalamus and the sympathetic nervous system, this mechanism enhances thermogenesis and cold tolerance and may help guide new treatments for obesity and diabetes.

January 27, 2026 01:06